GT Biopharma

GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical-stage immuno-oncology company focused on developing innovative therapies based on its proprietary NK cell engager (TriKE™) technology. TriKE™ therapeutics are targeted immunotherapeutic agents that simultaneously engage natural killer (NK) cells and cancer cells to selectively promote the killing of cancer cells. Using its proprietary platform technology, GT Biopharma is developing novel immuno-oncology biologics for the treatment of cancers including acute lymphoblastic leukemia, non-Hodgkin lymphoma, acute myeloid leukemia, and various solid tumors.